Fluorescence in situ hybridization for detecting urothelial carcinoma: A clinicopathologic study

Cancer Cytopathology

Volumn 118, Issue 5, 2010, Pages 259-268

  Caraway, Nancy P ^a   Khanna, Abha ^a   Fernandez, Ricardo L ^a   Payne, Linda ^a   Bassett Jr , Roland L ^a   Zhang, Hua Zhong ^a   Kamat, Ashish ^a   Katz, Ruth L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bladder neoplasms; Chromosomal abnormalities; Cytology; Fluorescence in situ hybridization (FISH); Multitarget FISH; Urine; Urothelial carcinoma; UroVysion

Indexed keywords

AGED; ARTICLE; BLADDER TUMOR; CYTODIAGNOSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FLUORESCENCE MICROSCOPY; FOLLOW UP; GENETICS; HUMAN; MALE; METABOLISM; METHODOLOGY; PATHOLOGY; REPRODUCIBILITY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; URINE; UROTHELIUM;

AGED; CYTODIAGNOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MICROSCOPY, FLUORESCENCE; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 79952111238     PISSN: None     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.20099     Document Type: Article

References (38)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Junker K, Fritsch T, Hartmann A, Schulze W, Schubert J. Multicolor fluorescence in situ hybridization (M-FISH) on cells from urine for the detection of bladder cancer. Cytogenet Genome Res. 2006;114:279-283.
3. Halling KC, Kipp BR. Bladder cancer detection using FISH (UroVysion assay). Adv Anat Pathol. 2008;15:279-286.
4. Black PC, Brown GA, Dinney CP. Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer. J Clin Oncol. 2006;24:5528-5535.
5. Halling KC, King W, Sokolova IA, et al. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis Uro- Vysion assays for the detection of urothelial carcinoma in urine. J Urol. 2002;167:2001-2006.
6. Glas AS, Roos D, Deutekom M, Zwinderman AH, Bossuyt PM, Kurth KH. Tumor markers in the diagnosis of primary bladder cancer. A systematic review. J Urol. 2003;169:1975-1982.
7. Budman LI, Kassouf W, Steinberg JR. Biomarkers for detection and surveillance of bladder cancer. Can Urol Assoc J. 2008;2:212-221.
8. Sharma S, Zippe CD, Pandrangi L, Nelson D, Agarwal A. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol. 1999;162: 53-57.
9. Svatek RS, Sagalowsky AI, Lotan Y. Economic impact of screening for bladder cancer using bladder tumor markers: a decision analysis. Urol Oncol. 2006;24:338-343.
10. Grossman HB, Soloway M, Messing E, et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA. 2006;295:299-305.
11. Baffa R, Letko J, McClung C, LeNoir J, Vecchione A, Gomella LG. Molecular genetics of bladder cancer: targets for diagnosis and therapy. J Exp Clin Cancer Res. 2006;25: 145-160.
12. Sokolova IA, Halling KC, Jenkins RB, et al. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn. 2000;2:116-123.
13. Halling KC, King W, Sokolova IA, et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol. 2000;164:1768-1775.
14. Sullivan PS, Nooraie F, Sanchez H, et al. Comparison of ImmunoCyt, UroVysion, and urine cytology in detection of recurrent urothelial carcinoma: a "split-sample" study. Cancer (Cancer Cytopathol). 2009;117:167-173.
15. Moonen PM, Merkx GF, Peelen P, Karthaus HF, Smeets DF, Witjes JA. UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscleinvasive bladder cancer. Eur Urol. 2007;51:1275-1280; discussion 80.
16. Landman J, Chang Y, Kavaler E, Droller MJ, Liu BC. Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer. Urology. 1998;52: 398-402.
17. Laudadio J, Keane TE, Reeves HM, et al. Fluorescence in situ hybridization for detecting transitional cell carcinoma: implications for clinical practice. BJU Int. 2005;96:1280-1285.
18. Sarosdy MF, Schellhammer P, Bokinsky G, et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol. 2002;168: 1950-1954.
19. Placer J, Espinet B, Salido M, Sole F, Gelabert-Mas A. Clinical utility of a multiprobe FISH assay in voided urine specimens for the detection of bladder cancer and its recurrences, compared with urinary cytology. Eur Urol. 2002;42: 547-552.
20. Dalquen P, Kleiber B, Grilli B, Herzog M, Bubendorf L, Oberholzer M. DNA image cytometry and fluorescence in situ hybridization for noninvasive detection of urothelial tumors in voided urine. Cancer. 2002;96:374-379.
21. Constantinou M, Binka-Kowalska A, Borkowska E, et al. Application of multiplex FISH, CGH and MSSCP techniques for cytogenetic and molecular analysis of transitional cell carcinoma (TCC) cells in voided urine specimens. J Appl Genet. 2006;47:273-275.
22. Sarosdy MF, Kahn PR, Ziffer MD, et al. Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria. J Urol. 2006;176:44-47.
23. SkacelM, Fahmy M, Brainard JA, et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol. 2003;169:2101-2105.
24. Marin-Aguilera M, Mengual L, Ribal MJ, et al. Utility of a multiprobe fluorescence in situ hybridization assay in the detection of superficial urothelial bladder cancer. Cancer Genet Cytogenet. 2007;173:131-135.
25. Hajdinjak T. UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. Urol Oncol. 2008;26:646-651.
26. Riesz P, Lotz G, Paska C, et al. Detection of bladder cancer from the urine using fluorescence in situ hybridization technique. Pathol Oncol Res. 2007;13:187-194.
27. Bollmann M, Heller H, Bankfalvi A, Griefingholt H, Bollmann R. Quantitative molecular urinary cytology by fluorescence in situ hybridization: a tool for tailoring surveillance of patients with superficial bladder cancer? BJU Int. 2005;95:1219-1225.
28. Bubendorf L, Grilli B, Sauter G, Mihatsch MJ, Gasser TC, Dalquen P. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol. 2001;116:79-86.
29. Skacel M, Pettay JD, Tsiftsakis EK, Procop GW, Biscotti CV, Tubbs RR. Validation of a multicolor interphase fluorescence in situ hybridization assay for detection of transitional cell carcinoma on fresh and archival thin-layer, liquid-based cytology slides. Anal Quant Cytol Histol. 2001; 23:381-387.
30. Yoder BJ, Skacel M, Hedgepeth R, et al. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol. 2007;127:295-301.
31. Savic S, Zlobec I, Thalmann GN, et al. The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guerin therapy. Int J Cancer. 2009;124:2899-2904.
32. Kipp BR, Karnes RJ, Brankley SM, et al. Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. J Urol. 2005;173:401-404.
33. Kipp BR, Fritcher EG, del Rosario KM, Stevens CL, Sebo TJ, Halling KC. A systematic approach to identifying urothelial cells likely to be polysomic by fluorescence in situ hybridization. Anal Quant Cytol Histol. 2005;27:317-322.
34. Zellweger T, Benz G, Cathomas G, et al. Multi-target fluorescence in situ hybridization in bladder washings for prediction of recurrent bladder cancer. Int J Cancer. 2006;119: 1660-1665.
35. Kipp BR, Sebo TJ, Griffin MD, Ihrke JM, Halling KC. Analysis of polyomavirus-infected renal transplant recipients' urine specimens: correlation of routine urine cytology, fluorescence in situ hybridization, and digital image analysis. Am J Clin Pathol. 2005;124:854-861.
36. von Willebrand E, Savikko J, Merenmies J, Jalanko H. Human polyoma virus in kidney transplants: SV40 T-antigen demonstration in the urine. Transplant Proc. 2005;37: 945-946.
37. Cimbaluk D, Pitelka L, Kluskens L, Gattuso P. Update on human polyomavirus BK nephropathy. Diagn Cytopathol. 2009;37:773-779.
38. Wojcik EM, Bassler TJ Jr, Orozco R. DNA ploidy in seminal vesicle cells. A potential diagnostic pitfall in urine cytology. Anal Quant Cytol Histol. 1999;21:29-34.